---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-047842"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T17:56:34.574104+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# INBS fingerprint drug test achieves 94.1% accuracy; FDA submission on track for Q4 2024

## Summary
- Method comparison study with 135 donors and 9 operators shows 94.1% accuracy, 82.2% sensitivity, 100% specificity for opiate detection.
- FDA 510(k) submission expected in Q4 2024; includes data from PK study and method study.
- System components evaluated: Drug Screening Cartridge, Reader, and Fingerprint Collection Kit.
- CEO Harry Simeonidis states results reaffirm accuracy and reliability for workplace drug testing.

## SEC filing metadata
- accession: 0001493152-24-047842
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315224047842/0001493152-24-047842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315224047842/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-047842
- JSON: https://secwatch.observer/filing/0001493152-24-047842.json
- Plain text: https://secwatch.observer/filing/0001493152-24-047842.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.